• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Disposition of chloroquine in man after single intravenous and oral doses.单次静脉注射和口服剂量后氯喹在人体内的处置情况。
Br J Clin Pharmacol. 1983 Apr;15(4):471-9. doi: 10.1111/j.1365-2125.1983.tb01532.x.
2
The disposition of chloroquine in healthy Nigerians after single intravenous and oral doses.单次静脉注射和口服给药后氯喹在健康尼日利亚人中的处置情况。
Br J Clin Pharmacol. 1987 Mar;23(3):295-301. doi: 10.1111/j.1365-2125.1987.tb03048.x.
3
Whole-blood single-dose kinetics of chloroquine and desethylchloroquine in Africans.非洲人氯喹和去乙基氯喹的全血单剂量动力学
Ther Drug Monit. 1986;8(2):195-9. doi: 10.1097/00007691-198606000-00012.
4
Enantioselective analysis of chloroquine and desethylchloroquine after oral administration of racemic chloroquine.口服消旋氯喹后氯喹和去乙基氯喹的对映体选择性分析。
Ther Drug Monit. 1986;8(4):457-61. doi: 10.1097/00007691-198612000-00014.
5
The single dose kinetics of chloroquine and its major metabolite desethylchloroquine in healthy subjects.氯喹及其主要代谢产物去乙基氯喹在健康受试者中的单剂量动力学。
Eur J Clin Pharmacol. 1984;26(4):521-30. doi: 10.1007/BF00542151.
6
Influence of route of administration on the pharmaco-kinetics of chloroquine and desethylchloroquine.给药途径对氯喹和脱乙基氯喹药代动力学的影响。
Bull World Health Organ. 1987;65(1):47-50.
7
Cardiovascular toxicity and distribution kinetics of intravenous chloroquine.静脉注射氯喹的心血管毒性及分布动力学
Br J Clin Pharmacol. 1986 Jul;22(1):31-6. doi: 10.1111/j.1365-2125.1986.tb02876.x.
8
Plasma chloroquine and desethylchloroquine concentrations in children during and after chloroquine treatment for malaria.疟疾氯喹治疗期间及之后儿童血浆中氯喹和去乙基氯喹的浓度
Br J Clin Pharmacol. 1983 Dec;16(6):701-5. doi: 10.1111/j.1365-2125.1983.tb02244.x.
9
Further support for changes in chloroquine disposition and metabolism between a low and a high dose.
Eur J Clin Pharmacol. 1985;28(6):721-2. doi: 10.1007/BF00607924.
10
Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs.1-(2-氯乙基)-3-肌氨酸酰胺-1-亚硝基脲对小鼠和犬静脉注射及口服给药后的血浆药代动力学和生物利用度
Cancer Chemother Pharmacol. 2001 Sep;48(3):202-8. doi: 10.1007/s002800100326.

引用本文的文献

1
Relationship Between Chloroquine or Hydroxychloroquine Use and Hearing Disorders: A Systematic Review and Meta-Analysis.氯喹或羟氯喹的使用与听力障碍之间的关系:一项系统评价和荟萃分析
J Audiol Otol. 2024 Apr;28(2):126-145. doi: 10.7874/jao.2023.00157. Epub 2024 Feb 22.
2
Biologic Functions of Hydroxychloroquine in Disease: From COVID-19 to Cancer.羟氯喹在疾病中的生物学功能:从新冠病毒疾病到癌症
Pharmaceutics. 2022 Nov 22;14(12):2551. doi: 10.3390/pharmaceutics14122551.
3
Effect of Binding Linkers on the Efficiency and Metabolite Profile of Biomimetic Reactions Catalyzed by Immobilized Metalloporphyrin.连接子对固定化金属卟啉催化的仿生反应效率和代谢物谱的影响
Metabolites. 2022 Dec 15;12(12):1269. doi: 10.3390/metabo12121269.
4
Population Pharmacokinetics of Antimalarial Naphthoquine in Combination with Artemisinin in Tanzanian Children and Adults: Dose Optimization.抗疟药萘酚喹与青蒿素联合在坦桑尼亚儿童和成人中的群体药代动力学:剂量优化。
Antimicrob Agents Chemother. 2022 May 17;66(5):e0169621. doi: 10.1128/aac.01696-21. Epub 2022 Apr 25.
5
Biomimetic properties and estimated in vivo distribution of chloroquine and hydroxy-chloroquine enantiomers.氯喹和羟基氯喹对映体的仿生特性及体内分布估计
ADMET DMPK. 2020 Jan 25;9(2):151-165. doi: 10.5599/admet.929. eCollection 2021.
6
Pulmonary Delivery of Aerosolized Chloroquine and Hydroxychloroquine to Treat COVID-19: In Vitro Experimentation to Human Dosing Predictions.气溶胶化氯喹和羟氯喹肺部给药治疗 COVID-19:从体外实验到人体剂量预测。
AAPS J. 2022 Feb 7;24(1):33. doi: 10.1208/s12248-021-00666-x.
7
The Ototoxicity of Chloroquine and Hydroxychloroquine: A Systematic Review.氯喹和羟氯喹的耳毒性:一项系统评价
Int Arch Otorhinolaryngol. 2022 Jan 25;26(1):e167-e177. doi: 10.1055/s-0041-1740986. eCollection 2022 Jan.
8
Aminoquinolines as Translational Models for Drug Repurposing: Anticancer Adjuvant Properties and Toxicokinetic-Related Features.氨基喹啉类药物作为药物重新利用的转化模型:抗癌辅助特性及与毒代动力学相关的特征
J Oncol. 2021 Sep 3;2021:3569349. doi: 10.1155/2021/3569349. eCollection 2021.
9
Lupus Nephritis and Hydroxychloroquine-Associated Zebra Bodies: Not Just in Fabry Disease.狼疮性肾炎与羟氯喹相关的斑马小体:并非仅见于法布里病。
Kidney Med. 2021 Mar 18;3(3):442-446. doi: 10.1016/j.xkme.2021.01.006. eCollection 2021 May-Jun.
10
Auditive and Vestibular Changes Related to the Use of Hydroxychlorochine and Chlorochine: An Integrative Review.与使用羟氯喹和氯喹相关的听觉和前庭变化:一项综合综述。
Int Arch Otorhinolaryngol. 2021 Apr;25(2):e309-e317. doi: 10.1055/s-0040-1722292. Epub 2021 Mar 29.

本文引用的文献

1
THE OTOTOXICITY OF CHLOROQUINE PHOSPHATE.
Arch Otolaryngol. 1964 Oct;80:407-12. doi: 10.1001/archotol.1964.00750040419009.
2
Determination of chloroquine and its desethyl metabolite in plasma, red blood cells and urine by liquid chromatography.采用液相色谱法测定血浆、红细胞和尿液中的氯喹及其去乙基代谢物。
J Chromatogr. 1982 Apr 16;229(1):241-7. doi: 10.1016/s0378-4347(00)86059-4.
3
Distribution of chloroquine and its metabolite desethyl-chloroquine in human blood cells and its implication for the quantitative determination of these compounds in serum and plasma.氯喹及其代谢产物去乙基氯喹在人体血细胞中的分布及其对血清和血浆中这些化合物定量测定的意义。
J Chromatogr. 1983 Jan 14;272(1):137-48. doi: 10.1016/s0378-4347(00)86110-1.
4
Improved fluorimetric assay of chloroquine in biological samples.
J Pharm Pharmacol. 1980 Oct;32(10):711-2. doi: 10.1111/j.2042-7158.1980.tb13045.x.
5
The metabolism of chloroquine in man during and after repeated oral dosage.
J Pharmacol Exp Ther. 1967 Nov;158(2):323-31.
6
Comparative bioavailabilities from truncated blood level curves.
J Pharm Sci. 1975 Sep;64(9):1521-4. doi: 10.1002/jps.2600640921.
7
Ototoxicity of chloroquine phosphate. A case report.
J Laryngol Otol. 1978 Aug;92(8):701-3. doi: 10.1017/s0022215100085960.
8
Chloroquine serum concentration and side effects: evidence for dose-dependent kinetics.
Clin Pharmacol Ther. 1979 Mar;25(3):345-50. doi: 10.1002/cpt1979253345.

单次静脉注射和口服剂量后氯喹在人体内的处置情况。

Disposition of chloroquine in man after single intravenous and oral doses.

作者信息

Gustafsson L L, Walker O, Alván G, Beermann B, Estevez F, Gleisner L, Lindström B, Sjöqvist F

出版信息

Br J Clin Pharmacol. 1983 Apr;15(4):471-9. doi: 10.1111/j.1365-2125.1983.tb01532.x.

DOI:10.1111/j.1365-2125.1983.tb01532.x
PMID:6849784
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1427807/
Abstract

1 Chloroquine was given in 300 mg single doses as an i.v. infusion, an oral solution and as tablets at intervals of at least 56 days to 11 healthy volunteers. Concentrations of chloroquine and its metabolite desethylchloroquine were measured in plasma, erythrocytes and urine using h.p.l.c. 2 Chloroquine was detectable in all plasma samples up to 23 days and occasionally up to 52 days after dosage. Urinary concentrations were monitored up to 119 days. The disposition pattern was multiexponential reflecting extensive tissue binding of the drug. 3 After i.v. dosing the volume of distribution ranged from 116 to 285 l/kg and the apparent terminal half-life from 146 to 333 h. Total plasma clearance +/- s.d. was 712 +/- 166 ml/min and renal clearance 412 +/- 139 ml/min. The mean estimated urinary recovery of chloroquine was 47%, 42% and 46% after i.v., oral solution and tablets indicating nearly complete bioavailability. The corresponding figures for the metabolite were 7%, 10% and 12%. 4 The disposition of chloroquine in erythrocytes was parallel to that in plasma. The concentrations in erythrocytes were consistently 2 to 5 times higher than in plasma. 5 Subjective side effects like difficulties with swallowing and accommodation, diplopia and fatigue occurred during intravenous infusion and were closely related to plasma concentrations. No effect was seen on the electrocardiogram, mean arterial blood pressure and pulse rate. No adverse reactions were observed after the oral doses. High frequency audiometry did not reveal any significant hearing impairment for the group as a whole.

摘要
  1. 给11名健康志愿者静脉输注、口服溶液和片剂形式的氯喹,单剂量均为300mg,给药间隔至少为56天至11天。使用高效液相色谱法测定血浆、红细胞和尿液中氯喹及其代谢产物去乙基氯喹的浓度。2. 在给药后长达23天的所有血浆样本中均可检测到氯喹,偶尔在52天后仍可检测到。对尿液浓度监测长达119天。处置模式呈多指数型,反映了该药物在组织中的广泛结合。3. 静脉给药后,分布容积为116至285L/kg,表观终末半衰期为146至333小时。血浆总清除率±标准差为712±166ml/min,肾清除率为412±139ml/min。静脉输注、口服溶液和片剂给药后,氯喹的平均尿回收率估计分别为47%、42%和46%,表明生物利用度几乎完全。代谢产物的相应数字分别为7%、10%和12%。4. 氯喹在红细胞中的处置与在血浆中的处置平行。红细胞中的浓度始终比血浆中的高2至5倍。5. 静脉输注期间出现了如吞咽和调节困难、复视和疲劳等主观副作用,且与血浆浓度密切相关。对心电图、平均动脉血压和脉搏率无影响。口服给药后未观察到不良反应。高频听力测定未显示该组整体有任何明显的听力损害。